519 research outputs found
Photon-avalanche upconversion of red light into blue light in a thulium-doped fluorozirconate fibre
We report the investigation of the photon-avalanche effect in heavily thulium-doped fluorozirconate fibre. Pumping at red wavelengths, which are not resonant with the ground-state absorption, gives blue emission at 450nm and 480nm
Blue avalanche upconversion in Tm:ZBLAN fibre
We report the investigation of the photon avalanche effect in heavily doped Tm:ZBLAN fibre at room temperature. Pumping at 630nm to 650nm, which is not resonant with the ground state absorption, gives intense blue emissions at 450nm and 480nm. The time evolution of the absorption and emission show a slow decaying oscillation before steady state is reached
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
To determine whether MDR1 reversal by the addition of the P-glycoprotein
(P-gp) inhibitor PSC-833 to standard induction chemotherapy would improve
event-free survival (EFS), 419 untreated patients with acute myeloid
leukemia (AML) aged 60 years and older were randomized to receive 2
induction cycles of daunorubicin and cytarabine with or without PSC-833.
Patients in complete remission were then given 1 consolidation cycle
without PSC-833. Neither complete response (CR) rate (54% versus 48%; P =
.22), 5-year EFS (7% versus 8%; P = .53), disease-free survival (DFS; 13%
versus 17%; P = .06) nor overall survival (OS; 10% in both arms; P = .52)
were significantly improved in the PSC-833 arm. An integrated P-gp score
(IPS) was determined based on P-gp function and P-gp expression in AML
cells obtained prior to treatment. A higher IPS was associated with a
significantly lower CR rate and worse EFS and OS. There was no significant
interaction between IPS and treatment arm with respect to CR rate and
survival, indicating also a lack of benefit of PSC-833 in P-gp-positive
patients. The role of strategies aimed at inhibitory P-gp and other
drug-resistance mechanisms continues to be defined in the treatment of
patients with AML
Global Diagnostics of Ionospheric Absorption During X-Ray Solar Flares Based on 8- to 20-MHz Noise Measured by Over-the-Horizon Radars
An analysis of noise attenuation during 80 solar flares between 2013 and 2017 was carried out at frequencies 8â20Â MHz using 34 Super Dual Auroral Radar Network radars and the EKB ISTP SB RAS radar. The attenuation was determined on the basis of noise measurements performed by the radars during the intervals between transmitting periods. The location of the primary contributing ground sources of noise was found by consideration of the propagation paths of radar backscatter from the ground. The elevation angle for the ground echoes was determined through a new empirical model. It was used to determine the paths of the noise and the location of its source. The method was particularly well suited for daytime situations, which had to be limited for the most part to only two crossings through the D region. Knowing the radio path was used to determine an equivalent vertical propagation attenuation factor. The change in the noise during solar flares was correlated with solar radiation lines measured by GOES/XRS, GOES/EUVS, SDO/AIA, SDO/EVE, SOHO/SEM, and PROBA2/LYRA instruments. Radiation in the 1 to 8Â Ă
and near 100Â Ă
are shown to be primarily responsible for the increase in the radionoise absorption, and by inference, for an increase in the D and E region density. The data are also shown to be consistent with a radar frequency dependence having a power law with an exponent of â1.6. This study shows that a new data set can be made available to study D and E regions
Somatic alteration burden involving non-cancer genes predicts prognosis in early-stage non-small cell lung cancer
The burden of somatic mutations and neoantigens has been associated with improved survival in cancer treated with immunotherapies, especially non-small cell lung cancer (NSCLC). However, there is uncertainty about their effect on outcome in early-stage untreated cases. We posited that the burden of mutations in a specific set of genes may also contribute to the prognosis of early NSCLC patients. From a small cohort of 36 NSCLC cases, we were able to identify somatic mutations and copy number alterations in 865 genes that contributed to patient overall survival. Simply, the number of altered genes (NAG) among these 865 genes was associated with longer disease-free survival (hazard ratio (HR) = 0.153, p = 1.48 Ă 10â4). The gene expression signature distinguishing patients with high/low NAG was also prognostic in three independent datasets. Patients with a high NAG could be further stratified based on the presence of immunogenic mutations, revealing a further subgroup of stage I NSCLC with even better prognosis (85% with >5 years survival), and associated with cytotoxic T-cell expression. Importantly, 95% of the highly-altered genes lacked direct relation to cancer, but were implicated in pathways regulating cell proliferation, motility and immune response
Measurement of the Hadronic Photon Structure Function F_2^gamma at LEP2
The hadronic structure function of the photon F_2^gamma is measured as a
function of Bjorken x and of the factorisation scale Q^2 using data taken by
the OPAL detector at LEP. Previous OPAL measurements of the x dependence of
F_2^gamma are extended to an average Q^2 of 767 GeV^2. The Q^2 evolution of
F_2^gamma is studied for average Q^2 between 11.9 and 1051 GeV^2. As predicted
by QCD, the data show positive scaling violations in F_2^gamma. Several
parameterisations of F_2^gamma are in agreement with the measurements whereas
the quark-parton model prediction fails to describe the data.Comment: 4 pages, 2 figures, to appear in the proceedings of Photon 2001,
Ascona, Switzerlan
A measurement of the tau mass and the first CPT test with tau leptons
We measure the mass of the tau lepton to be 1775.1+-1.6(stat)+-1.0(syst.) MeV
using tau pairs from Z0 decays. To test CPT invariance we compare the masses of
the positively and negatively charged tau leptons. The relative mass difference
is found to be smaller than 3.0 10^-3 at the 90% confidence level.Comment: 10 pages, 4 figures, Submitted to Phys. Letts.
Supervised Treatment in Outpatients for Schizophrenia Plus (STOPS+): Protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan
Introduction: There is a significant treatment gap, with only a few community-based services for people with schizophrenia in Low- and Middle-Income countries. Poor treatment adherence in schizophrenia is associated with poorer health outcomes, suicide attempts and death. We previously reported the effectiveness of STOPS (Supervised Treatment in Outpatients for Schizophrenia) for improving treatment adherence in patients with schizophrenia. However, STOPS was evaluated in a tertiary care setting with no primary care involvement, limiting its generalisability to the wider at-risk population. We aim to evaluate the effectiveness of STOPS+ in scaling up the primary care treatment of schizophrenia to a real-world setting.
Methods and analysis: The effectiveness of the STOPS+ intervention in improving the level of functioning and medication adherence in patients with schizophrenia in Pakistan will be evaluated using a cluster randomised controlled trial design. We aim to recruit 526 participants from 24 Primary Health Care Centres (PHCs) randomly allocated in 1:1 ratio to STOPS+ intervention and Enhanced Treatment as Usual (ETAU) arms. Participants will be followed-up for 12 months post recruitment. The sample size is estimated for two outcomes (i) The primary clinical outcome is level of functioning, measured using the Global Assessment of Functioning (GAF) scale, and (ii) the primary process outcome is adherence to treatment regimen measured using a validated measure. An intention-to-treat approach will be used for the primary analysis.
Ethics and Dissemination: Ethical approval has been obtained from Keele University Ethical Review Panel (ref: MH-190017) and Khyber Medical University Ethical Review Board (ref: DIR-KMU-EB/ST/000648). The results of the STOPS+ trial will be reported in peer reviewed journals and academic conferences and disseminated to local stakeholders and policy makers
Measurement of the B0 Lifetime and Oscillation Frequency using B0->D*+l-v decays
The lifetime and oscillation frequency of the B0 meson has been measured
using B0->D*+l-v decays recorded on the Z0 peak with the OPAL detector at LEP.
The D*+ -> D0pi+ decays were reconstructed using an inclusive technique and the
production flavour of the B0 mesons was determined using a combination of tags
from the rest of the event. The results t_B0 = 1.541 +- 0.028 +- 0.023 ps, Dm_d
= 0.497 +- 0.024 +- 0.025 ps-1 were obtained, where in each case the first
error is statistical and the second systematic.Comment: 17 pages, 4 figures, submitted to Phys. Lett.
- âŠ